Category: Europe

AbbVie and We Are Pioneer Group Launch Golden Ticket Programme to Help UK Life Science Start-ups Accelerate the Delivery of Life-Changing Innovations to Patients
April 4, 2022 Off

AbbVie and We Are Pioneer Group Launch Golden Ticket Programme to Help UK Life Science Start-ups Accelerate the Delivery of Life-Changing Innovations to Patients

By Dino Mustafić

AbbVie, the global research-driven biopharmaceutical company and We Are Pioneer Group (WAPG), Europe’s largest ecosystem provider for science and innovation businesses, to support the thriving UK life sciences start-up community, has launched a programme designed to help early-stage life science companies commercialise drug discovery and gain access to crucial research space.

CardioRenal Raises €3.3M
April 4, 2022 Off

CardioRenal Raises €3.3M

By Author

CardioRenal, a company specialized in improving treatment at home for patients with severe chronic kidney disease (CKD), has secured funds of EUR 3.3 million ($3.7M) from business angels and longstanding company shareholders (the management) as part of a round of seed capital financing.

Sanofi Launches First-In-Pharma Diversity, Equity & Inclusion Board
April 4, 2022 Off

Sanofi Launches First-In-Pharma Diversity, Equity & Inclusion Board

By Author

Sanofi has launched its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors. Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand.

Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement
March 31, 2022 Off

Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement

By Author

Vivoryon Therapeutics N.V., a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, has announced the launch of a private placement by way of an accelerated bookbuilding process to institutional investors offering up to 2,000,000 newly issued registered shares, representing up to approximately 10% of the company’s issued share capital.